Company Announcements

RNS Number : 1042J
Hikma Pharmaceuticals Plc
25 April 2022


Hikma Pharmaceuticals PLC
25 April 2022



Withdrawal of 2022 AGM Resolution 15

The Board of Hikma Pharmaceuticals PLC ("Hikma" or the "Company") today announces that it has decided to withdraw Resolution 15 from the agenda of the Annual General Meeting ("2022 AGM") of the Company's shareholders to be held at 1.00 p.m. (London time) today, 25 April 2022.

Resolution 15, as set out in the notice of the 2022 AGM (the "2022 AGM Notice"), proposes the creation of distributable reserves in the capital of the Company by means of a bonus issue and a Court-sanctioned capital reduction (the "Relevant Business"). At the 2022 AGM, Resolution 15 will be withdrawn from the business of the meeting on account of a typographical error which resulted in Resolution 15 being incorrectly proposed as an ordinary resolution, rather than a special resolution, and consequently being of no legal effect.

Save as set out above, the 2022 AGM will proceed as planned later today in accordance with the arrangements previously notified. The withdrawal of Resolution 15 does not otherwise affect the validity of the 2022 AGM Notice, the proxy form or any proxy votes already submitted on other proposed resolutions. The numbering of all other proposed resolutions at the 2022 AGM will remain unchanged.

Publication of EGM Notice

In order to allow the Relevant Business to be properly considered by shareholders, the Company is today calling a separate general meeting of its shareholders to be held at 10 a.m. on 20 May 2022 at Hikma Offices, 5th Floor, 1 New Burlington Place, London W1S 2HR, United Kingdom (the "EGM").  The special resolution relating to the Relevant Business will be the single item of business at the EGM. Except to correct the typographical error in connection with Resolution 15 of the 2022 AGM Notice, there will be no changes to the text of the resolution or the accompanying explanatory note, each as originally contained in the 2022 AGM Notice.

Notice of the EGM will today be published and posted to those shareholders on the Company's register of members as at the close of business on 21 April 2022 who have elected to receive paper communications. In compliance with the UK Financial Conduct Authority's Listing Rules, the notice of EGM will shortly be submitted to, and available for inspection from, the National Storage Mechanism at

Full details of the business of, and arrangements for, the EGM (including voting procedures) are contained in the notice of the EGM. This announcement is not a substitute for reading the notice of the EGM in full.

Peter Speirs
Company Secretary

For and on behalf of
Hikma Pharmaceuticals PLC

25 April 2022



Peter Speirs
Company Secretary

+44 (0)20 7399 2772


About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.